Toremifene: an evaluation of its safety profile.

摘要: Toremifene has been in clinical use for 8 years the treatment of advanced hormone-sensitive breast cancer and adjuvant early cancer. More than 350,000 patient have accumulated, sufficient to allow evaluation its longer-term safety profile comparison with tamoxifen and, where possible, raloxifene aromatase inhibitors. We reviewed all preclinical data from 1978 2004 comparative between October 1995 end 2004. Secondary endometrial incidence was lower toremifene similar that raloxifene. It is speculated may unmask existing tumors rather induce new events. The risk stroke, pulmonary embolism, cataract be embolism deep vein thrombosis Beneficial estrogen agonistic effects were equivalent those regarding bone mineral density superior lipid profiles.